BeiGene's Brukin­sa wins CLL ap­proval af­ter top­ping Im­bru­vi­ca in head-to-head tri­al

The FDA green­lit BeiGene’s Brukin­sa for use in chron­ic lym­pho­cyt­ic leukemia, an ap­proval that should sub­stan­tial­ly ex­pand the mar­ket for the drug in the US af­ter it topped the cur­rent lead­ing ther­a­py in a tri­al.

The ap­proval, which is for re­lapsed/re­frac­to­ry and first-line treat­ment for adults with CLL as well as small lym­pho­cyt­ic lym­phoma, is the drug’s fourth US clear­ance. It comes af­ter BeiGene showed the twice-dai­ly oral drug beat the stan­dard of care, Ab­b­Vie and John­son & John­son’s Im­bru­vi­ca, in a head-to-head test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER